• Tocilizumab linked with highest risk for neutropenia in comparison study that included abatacept, infliximab

    One year ago - By Healio

    In a comparison study of abatacept, infliximab and tocilizumab for the treatment of 499 patients with rheumatic diseases, tocilizumab was linked with the highest risk of neutropenia.In their study, Francisco Espinoza, MD, in the Department of Rheumatology at Lapeyronie University Hospital and the University of Montpellier School of Medicine, and colleagues found rheumatoid arthritis was diagnosed in 72% of patients. In addition, 10.4% of patients had at least one episode of neutropenia and there were no episodes of grade 4 neutropenia.
    Read more ...